Antitumor effector B cells directly kill tumor cells via the Fas/FasL pathway and are regulated by IL-10

European Journal of Immunology

Volumn 45, Issue 4, 2015, Pages 999-1009

  Tao, Huimin ^a,b   Lu, Lin ^a,c   Xia, Yang ^a,d   Dai, Fu ^d   Wang, Yi ^d   Bao, Yangyi ^d   Lundy, Steven K ^a   Ito, Fumito ^a   Pan, Qin ^e   Zhang, Xiaolian ^e   Zheng, Fang ^b   Shu, Guoshun ^a,f   Fang, Bingmu ^g   Jiang, Jinhong ^g   Xia, Jianchuang ^c   Huang, Shiang ^b   Li, Qiao ^a,d   Chang, Alfred E ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

^b HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^c SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^d ANHUI MEDICAL UNIVERSITY   (China)

^e WUHAN UNIVERSITY   (China)

^f CENTRAL SOUTH UNIVERSITY   (China)

^g LISHUI PEOPLE S HOSPITAL   (China)

Author keywords

Adoptive Immunotherapy; B cells; Cytotoxicity; Fas; IL 10; Tumor

Indexed keywords

FAS ANTIGEN; FAS LIGAND; INTERLEUKIN 10; INTERLEUKIN 2; FASL PROTEIN, MOUSE;

ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL TISSUE; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ARTICLE; B LYMPHOCYTE; B LYMPHOCYTE ACTIVATION; CANCER INHIBITION; CELL DEATH; CELL EXPANSION; CELL MIGRATION; COCULTURE; COMPLEMENT DEPENDENT CYTOTOXICITY; CONTROLLED STUDY; EFFECTOR CELL; FEMALE; HUMORAL IMMUNITY; IN VITRO STUDY; IN VIVO STUDY; LYMPHOID ORGAN; METASTASIS INHIBITION; MOUSE; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN DEPLETION; SIGNAL TRANSDUCTION; TUMOR IMMUNITY; TUMOR REGRESSION; ADOPTIVE IMMUNOTHERAPY; ANIMAL; BAGG ALBINO MOUSE; BIOLOGICAL THERAPY; BIOSYNTHESIS; CELL MOTION; CYTOTOXIC T LYMPHOCYTE; GENETICS; IMMUNOLOGY; KNOCKOUT MOUSE; LYMPH NODE; LYMPHOCYTE ACTIVATION; NEOPLASMS; PROCEDURES; TRANSPLANTATION; TUMOR CELL LINE;

ANIMALS; ANTIGENS, CD95; B-LYMPHOCYTE SUBSETS; CELL LINE, TUMOR; CELL MOVEMENT; CELL- AND TISSUE-BASED THERAPY; FAS LIGAND PROTEIN; FEMALE; IMMUNOTHERAPY, ADOPTIVE; INTERLEUKIN-10; LYMPH NODES; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED BALB C; MICE, KNOCKOUT; NEOPLASMS; T-LYMPHOCYTES, CYTOTOXIC;

EID: 84926971363     PISSN: 00142980     EISSN: 15214141     Source Type: Journal    
DOI: 10.1002/eji.201444625     Document Type: Article

References (39)

1. Mellman, I., Coukos, G. and Dranoff, G., Cancer immunotherapy comes of age. Nature 2011. 480: 480-489.
2. Ward, B. A., Shu, S., Chou, T., Perry-Lalley, D. and Chang, A. E., Cellular basis of immunologic interactions in adoptive T cell therapy of established metastases from a syngeneic murine sarcoma. J. Immunol. 1988. 141: 1047-1053.
3. Chang, A. E., Perry-Lalley, D. M. and Shu, S., Distinct immunologic specificity of tumor regression mediated by effector cells isolated from immunized and tumor-bearing mice. Cell Immunol. 1989. 120: 419-429.
4. Geiger, J. D., Wagner, P. D., Cameron, M. J., Shu, S. and Chang, A. E., Generation of T cells reactive to the poorly immunogenic B16-BL6 melanoma with efficacy in the treatment of spontaneous metastases. J. Immunother. Emphasis Tumor Immunol. 1993. 13: 153-165.
5. Li, Q., Grover, A. C., Donald, E. J., Carr, A., Yu, J., Whitfield, J., Nelson, M. et al., Simultaneous targeting of CD3 on T cells and CD40 on B or dendritic cells augments the antitumor reactivity of tumor-primed lymph node cells. J. Immunol. 2005. 175: 1424-1432.
6. Iuchi, T., Teitz-Tennenbaum, S., Huang, J., Redman, B. G., Hughes, S. D., Li, M., Jiang, G. et al., Interleukin-21 augments the efficacy of T-cell therapy by eliciting concurrent cellular and humoral responses. Cancer Res. 2008. 68: 4431-4441.
7. Li, Q., Teitz-Tennenbaum, S., Donald, E. J., Li, M. and Chang, A. E., In vivo sensitized and in vitro activated B cells mediate tumor regression in cancer adoptive immunotherapy. J. Immunol. 2009. 183: 3195-3203.
8. Li, Q., Lao, X., Pan, Q., Ning, N., Yet, J., Xu, Y., Li, S. and Chang, A. E., Adoptive transfer of tumor reactive B cells confers host T-cell immunity and tumor regression. Clin. Cancer Res. 2011. 17: 4987-4995.
9. Mauri, C. and Ehrenstein, M. R., The 'short' history of regulatory B cells. Trends Immunol 2008. 29: 34-40.
10. Lapointe, R., Bellemare-Pelletier, A., Housseau, F., Thibodeau, J. and Hwu, P., CD40-stimulated B lymphocytes pulsed with tumor antigens are effective antigen-presenting cells that can generate specific T cells. Cancer Res. 2003. 63: 2836-2843.
11. Lundy, S. K., Killer B lymphocytes: the evidence and the potential. Inflamm. Res. 2009. 58: 345-357.
12. Perricone, M. A., Smith, K. A., Claussen, K. A., Plog, M. S., Hempel, D. M., Roberts, B. L., St George, J. A. and Kaplan, J. M., Enhanced efficacy of melanoma vaccines in the absence of B lymphocytes. J. Immunother. 2004. 27: 273-281.
13. Qin, Z., Richter, G., Schuler, T., Ibe, S., Cao, X. and Blankenstein, T., B cells inhibit induction of T cell-dependent tumor immunity. Nat. Med. 1998. 4: 627-630.
14. Shah, S., Divekar, A. A., Hilchey, S. P., Cho, H. M., Newman, C. L., Shin, S. U., Nechustan, H. et al., Increased rejection of primary tumors in mice lacking B cells: inhibition of anti-tumor CTL and TH1 cytokine responses by B cells. Int. J. Cancer 2005. 117: 574-586.
15. Evans, D. E., Munks, M. W., Purkerson, J. M. and Parker, D. C., Resting B lymphocytes as APC for naive T lymphocytes: dependence on CD40 ligand/CD40. J. Immunol. 2000. 164: 688-697.
16. Mizoguchi, A., Mizoguchi, E., Takedatsu, H., Blumberg, R. S. and Bhan, A. K., Chronic intestinal inflammatory condition generates IL-10-producing regulatory B cell subset characterized by CD1d upregulation. Immunity 2002. 16: 219-230.
17. Fillatreau, S., Sweenie, C. H., McGeachy, M. J., Gray, D. and Anderton, S. M., B cells regulate autoimmunity by provision of IL-10. Nat. Immunol. 2002. 3: 944-950.
18. Mauri, C., Gray, D., Mushtaq, N. and Londei, M., Prevention of arthritis by interleukin 10-producing B cells. J. Exp. Med. 2003. 197: 489-501.
19. Inoue, S., Leitner, W. W., Golding, B. and Scott, D., Inhibitory effects of B cells on antitumor immunity. Cancer Res. 2006. 66: 7741-7747.
20. Schioppa, T., Moore, R., Thompson, R. G., Rosser, E. C., Kulbe, H., Nedospasov, S., Mauri, C. et al., B regulatory cells and the tumor-promoting actions of TNF-alpha during squamous carcinogenesis. Proc. Natl. Acad. Sci. USA 2011. 108: 10662-10667.
21. Yanaba, K., Bouaziz, J. D., Matsushita, T., Tsubata, T. and Tedder, T. F., The development and function of regulatory B cells expressing IL-10 (B10 cells) requires antigen receptor diversity and TLR signals. J. Immunol. 2009. 182: 7459-7472.
22. DiLillo, D. J., Matsushita, T. and Tedder, T. F., B10 cells and regulatory B cells balance immune responses during inflammation, autoimmunity, and cancer. Ann. NY Acad. Sci. 2010. 1183: 38-57.
23. Evans, J. G., Chavez-Rueda, K. A., Eddaoudi, A., Meyer-Bahlburg, A., Rawlings, D. J., Ehrenstein, M. R. and Mauri, C., Novel suppressive function of transitional 2 B cells in experimental arthritis. J. Immunol. 2007. 178: 7868-7878.
24. Yanaba, K., Bouaziz, J. D., Haas, K. M., Poe, J. C., Fujimoto, M. and Tedder, T. F., A regulatory B cell subset with a unique CD1dhiCD5+ phenotype controls T cell-dependent inflammatory responses. Immunity 2008. 28: 639-650.
25. Matsushita, T., Yanaba, K., Bouaziz, J. D., Fujimoto, M. and Tedder, T. F., Regulatory B cells inhibit EAE initiation in mice while other B cells promote disease progression. J. Clin. Invest. 2008. 118: 3420-3430.
26. Koni, P. A., Bolduc, A., Takezaki, M., Ametani, Y., Huang, L., Lee, J. R., Nutt, S. L. et al., Constitutively CD40-activated B cells regulate CD8 T cell inflammatory response by IL-10 induction. J. Immunol. 2013. 190: 3189-3196.
27. Klinker, M. W. and Lundy, S. K., Multiple mechanisms of immune suppression by B lymphocytes. Mol. Med. 2012. 18: 123-137.
28. Hahne, M., Renno, T., Schroeter, M., Irmler, M., French, L., Bornard, T., MacDonald, H. R. and Tschopp, J., Activated B cells express functional Fas ligand. Eur. J. Immunol. 1996. 26: 721-724.
29. Strater, J., Mariani, S. M., Walczak, H., Rucker, F. G., Leithauser, F., Krammer, P. H. and Moller, P., CD95 ligand (CD95L) in normal human lymphoid tissues: a subset of plasma cells are prominent producers of CD95L. Am. J. Pathol. 1999. 154: 193-201.
30. Blair, P. A., Chavez-Rueda, K. A., Evans, J. G., Shlomchik, M. J., Eddaoudi, A., Isenberg, D. A., Ehrenstein, M. R. and Mauri, C., Selective targeting of B cells with agonistic anti-CD40 is an efficacious strategy for the generation of induced regulatory T2-like B cells and for the suppression of lupus in MRL/lpr mice. J. Immunol. 2009. 182: 3492-3502.
31. Maseda, D., Candando, K. M., Smith, S. H., Kalampokis, I., Weaver, C. T., Plevy, S. E., Poe, J. C. and Tedder, T. F., Peritoneal cavity regulatory B cells (B10 cells) modulate IFN-gamma+CD4+ T cell numbers during colitis development in mice. J. Immunol. 2013. 191: 2780-2795.
32. Aruga, A., Aruga, E., Tanigawa, K., Bishop, D. K., Sondak, V. K. and Chang, A. E., Type 1 versus type 2 cytokine release by Vbeta T cell subpopulations determines in vivo antitumor reactivity: IL-10 mediates a suppressive role. J. Immunol. 1997. 159: 664-673.
33. Nilsson, N., Ingvarsson, S. and Borrebaeck, C. A., Immature B cells in bone marrow express Fas/FasL. Scand. J. Immunol. 2000. 51: 279-284.
34. Tian, J., Zekzer, D., Hanssen, L., Lu, Y., Olcott, A. and Kaufman, D. L., Lipopolysaccharide-activated B cells down-regulate Th1 immunity and prevent autoimmune diabetes in nonobese diabetic mice. J. Immunol. 2001. 167: 1081-1089.
35. Klinker, M. W., Reed, T. J., Fox, D. A. and Lundy, S. K., Interleukin-5 supports the expansion of fas ligand-expressing killer B cells that induce antigen-specific apoptosis of CD4(+) T cells and secrete interleukin-10. PLoS One 2013. 8: e70131.
36. Harada, M., Okamoto, T., Kurosawa, S., Shinomiya, Y., Ito, O., Takenoyama, M., Terao, H. et al., The antitumor activity induced by the in vivo administration of activated B cells bound to anti-CD3 monoclonal antibody. Cell Immunol. 1995. 161: 132-137.
37. Messina, J. L., Fenstermacher, D. A., Eschrich, S., Qu, X., Berglund, A. E., Lloyd, M. C., Schell, M. J. et al., 12-Chemokine gene signature identifies lymph node-like structures in melanoma: potential for patient selection for immunotherapy? Sci. Rep. 2012. 2: 765.
38. Brennen, W. N., Drake, C. G. and Isaacs, J. T., Enhancement of the T-cell armamentarium as a cell-based therapy for prostate cancer. Cancer Res. 2014. 74: 3390-3395.
39. Skitzki, J., Craig, R. A., Okuyama, R., Knibbs, R. N., McDonagh, K., Chang, A. E. and Stoolman, L. M., Donor cell cycling, trafficking, and accumulation during adoptive immunotherapy for murine lung metastases. Cancer Res. 2004. 64: 2183-2191.